Molecular Stool Testing Could Cut Post-Polypectomy Colonoscopies by 15%-41% (Medscape)

The Dutch MOCCAS study suggests that noninvasive stool-based surveillance using FIT or multitarget DNA tests could match colonoscopy in reducing long-term colorectal cancer (CRC) incidence and mortality, potentially lowering colonoscopy use by 15%-41%. Annual FIT-based monitoring, particularly with FIT FOB-Gold, showed the highest effectiveness and cost savings. While multitarget DNA testing outperformed FIT for detecting advanced lesions, including serrated polyps, it remains more expensive than colonoscopy surveillance.